Ok i've always been confident that Phylogica was tied to Genentechs BBB X in 2011 as i've posted many times & obviously NW's reply in the days following are obviously what was going to be put up in the face of confidentialty agreements but assuming they were on the money & correct then i guess we still can't assume any different with accuracy until the time comes that it is formalised however i'm just going to pull up a few points that i have always questioned in my head contrary to my gut saying it was all linked.
Firstly i'll just repost 2 parts of NW's via email in the days following both the extension & then the X of 2011 -
"there is no connection between our collaboration with Roche and Genentech's recent news about BBB delivery."
"be assured that we are moving forward with Roche on PEPTIDES (not antibodies) that cross the BBB. If anything, their interest is greater than ever. We aim to report more news from that relationship well within the current calendar year. Yes, the deal was re-negotiated."
Secondly i also seem to recall the PYC/Roche collaboration was still in Basel at the time Genentechs cross actually happened but then as Roche restructured operations in Basel they were transferred to Genentech in the US however this was after Genentech made the cross ? ? ? i can't be certain there but i'm pretty sure it was after & Roches restructuring of Basel was one of the events that slowed progress of the whole PYC/Roche collaboration ?
Still confident it's tight in there & i seem to recall Genetech ran into problems with the original cross the further they took it ? so while maybe it wasn't a phylomer to start with it may very well be now.
Finally people have been trying to hit this spot for a very very long time it really is the holy grail (and i really dont like that word - because it's usually never found but i will here lol) many have come close but no cigar, i think (a big assumption) Genentech may be very close & phylomer holds the key although it's not quite there yet. If they had the key & proof was undeniable then firstly there wouldn't be any more deals there wouldn't be discussion for new expanded collaborations the elusive key would be aquired everything else would just go with the bundle, big pharma is not going to idle with that kind of break. In the meantime it also wouldn't be trading paper weight volumes with $10M market value.
All in time - & hopefully that time is soon :-)
Add to My Watchlist
What is My Watchlist?
